Brent Saunders, Bausch + Lomb CEO (Roam)
City Therapeutics, Bausch + Lomb partner on preclinical RNAi eye drug
With its new CEO installed this week, City Therapeutics is aiming to capitalize on the momentum in signing a new deal.
The startup is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
